Skip to main content
Erschienen in: Wiener Medizinische Wochenschrift 15-16/2013

01.08.2013 | case report

Atypical fibroxanthoma—a diagnosis of exclusion!

verfasst von: Assoc. Prof. Georgi Tchernev, Prof. Michael Tronnier, MD, Julian Ananiev, MD, PhD, Teodora Taneva, Prof. James W. Patterson, MD, Assoc. Prof. Maya Gulubova, MD, PhD, John P. Trafeli, Assoc. Prof. Antonina Gegova, Mason Harrell, MD, Claudio Guarneri, MD, Prof. Uwe Wollina, MD, José Carlos Cardoso, MD, Nobuo Kanazawa, MD, PhD, Assoc. Prof. Liliya Zisova, MD, PhD, Assist. Prof. Ana-Maria Forsea, MD, PhD, Prof. Christos C. Zouboulis

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 15-16/2013

Einloggen, um Zugang zu erhalten

Summary

Fibrohistiocytic tumors of the skin comprise a large range of lesions. One such tumor is the atypical fibroxanthoma (AFX), which is widely considered as a “pseudomalignant” tumor. It is derived from fibroblasts and expresses a variety of histiocytic markers. We present a case of AFX, localized in the right temporal region of the scalp, successfully treated with surgical excision. Immunohistochemical staining helps differentiate this tumor from others in the clinical differential diagnosis, including malignant melanoma, squamous cell carcinoma, and other nonmelanocytic spindle cell tumors such as leiomyosarcoma, rhabdomyosarcoma, angiosarcoma, liposarcoma, and dermatofibrosarcoma protuberans. Historically, AFX was believed to be a superficial variant of malignant fibrous histiocytoma (MFH). However, MFH is now considered a more generalized term for a sarcomatous neoplasm of the subcutaneous tissue. The histopathology of MFH shares features with some malignant mesenchymal neoplasms such as liposarcoma, leiomyosarcoma, rhabdomyosarcoma, and angiosarcoma, but can be differentiated using immunohistochemistry and/or electron microscopy. More recently, the examples of MFH that do not exhibit a more specific line of differentiation have been reclassified as undifferentiated pleomorphic sarcoma (UPS). Many authors currently cannot draw a distinction between AFX and UPS. The clinical and histopathological differences between AFX and UPS are often difficult to delineate. It is probable that they represent two poles of the same disease. Surgical excision in the patient we describe resulted in excellent aesthetic results with lack of recurrence in the 7-month postoperative period.
Literatur
1.
Zurück zum Zitat Helwig EB. Atypical fibroxanthoma. Tex State J Med. 1963;59:664–7. Helwig EB. Atypical fibroxanthoma. Tex State J Med. 1963;59:664–7.
2.
Zurück zum Zitat Ziemer M. Atypical fibroxanthoma. J Dtsch Dermatol Ges. 2012;10(8):537–50.PubMed Ziemer M. Atypical fibroxanthoma. J Dtsch Dermatol Ges. 2012;10(8):537–50.PubMed
3.
Zurück zum Zitat Mirza B, Weedon D. Atypical fibroxanthoma: a clinicopathological study of 89 cases. Australas J Dermatol. 2005;46(4):235–8.PubMedCrossRef Mirza B, Weedon D. Atypical fibroxanthoma: a clinicopathological study of 89 cases. Australas J Dermatol. 2005;46(4):235–8.PubMedCrossRef
4.
Zurück zum Zitat Dahl I. Atypical fibroxanthoma of the skin. A clinico-pathological study of 57 cases. Acta Pathol Microbiol Scand A. 1976;84(2):183–97.PubMed Dahl I. Atypical fibroxanthoma of the skin. A clinico-pathological study of 57 cases. Acta Pathol Microbiol Scand A. 1976;84(2):183–97.PubMed
5.
Zurück zum Zitat Longacre TA, Smoller BR, Rouse RV. Atypical fibroxanthoma. Multiple immunohistologic profiles. Am J Surg Pathol. 1993;17(12):1199–209.PubMedCrossRef Longacre TA, Smoller BR, Rouse RV. Atypical fibroxanthoma. Multiple immunohistologic profiles. Am J Surg Pathol. 1993;17(12):1199–209.PubMedCrossRef
6.
7.
Zurück zum Zitat Fletcher CD. Pleomorphic malignant fibrous histiocystoma: fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma. Am J Surg Pathol. 1992;16(3): 213–28.PubMedCrossRef Fletcher CD. Pleomorphic malignant fibrous histiocystoma: fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma. Am J Surg Pathol. 1992;16(3): 213–28.PubMedCrossRef
8.
Zurück zum Zitat Fletcher CDM. WHO classification of tumours: pathology and genetics of tumours of soft tissue and bone. Lyon: IARC; 2002. pp. 120–6. Fletcher CDM. WHO classification of tumours: pathology and genetics of tumours of soft tissue and bone. Lyon: IARC; 2002. pp. 120–6.
9.
Zurück zum Zitat Withers AH, Brougham ND, Barber RM, Tan ST. Atypical fibroxanthoma and malignant fibrous histiocytoma. J Plast Reconstr Aesthet Surg. 2011;64(11):e273–8.PubMedCrossRef Withers AH, Brougham ND, Barber RM, Tan ST. Atypical fibroxanthoma and malignant fibrous histiocytoma. J Plast Reconstr Aesthet Surg. 2011;64(11):e273–8.PubMedCrossRef
10.
Zurück zum Zitat Lazova R, Moynes R, May D, Scott G. LN-2 (CD-74). A marker to distinguish atypical fibroxanthoma from malignant fibrous histiocytoma. Cancer. 1997;79(11):2115–24.PubMedCrossRef Lazova R, Moynes R, May D, Scott G. LN-2 (CD-74). A marker to distinguish atypical fibroxanthoma from malignant fibrous histiocytoma. Cancer. 1997;79(11):2115–24.PubMedCrossRef
11.
Zurück zum Zitat Marburger TB, Gardner JM, Prieto VG, Billings SD. Primary cutaneous rhabdomyosarcoma: a clinicopathologic review of 11 cases. J Cutan Pathol. 2012;39(11):987–95 (Epub 21 Sept 2012).PubMedCrossRef Marburger TB, Gardner JM, Prieto VG, Billings SD. Primary cutaneous rhabdomyosarcoma: a clinicopathologic review of 11 cases. J Cutan Pathol. 2012;39(11):987–95 (Epub 21 Sept 2012).PubMedCrossRef
13.
Zurück zum Zitat Sigel JE, Skacel M, Bergfeld WF, House NS, Rabkin MS, Goldblum JR. The utility of cytokeratin 5/6 in the recognition of cutaneous spindle cell squamous cell carcinoma. J Cutan Pathol. 2001;28(10):520–4.PubMedCrossRef Sigel JE, Skacel M, Bergfeld WF, House NS, Rabkin MS, Goldblum JR. The utility of cytokeratin 5/6 in the recognition of cutaneous spindle cell squamous cell carcinoma. J Cutan Pathol. 2001;28(10):520–4.PubMedCrossRef
14.
Zurück zum Zitat Gray Y, Robidoux HJ, Farrell DS, Robinson-Bostom L. Squamous cell carcinoma detected by high-molecular-weight cytokeratin immunostaining mimicking atypical fibroxanthoma. Arch Pathol Lab Med. 2001;125(6):799–802.PubMed Gray Y, Robidoux HJ, Farrell DS, Robinson-Bostom L. Squamous cell carcinoma detected by high-molecular-weight cytokeratin immunostaining mimicking atypical fibroxanthoma. Arch Pathol Lab Med. 2001;125(6):799–802.PubMed
15.
Zurück zum Zitat Zelger B, Soyer HP. Between Scylla and Charybdis; mythology in dermatopathology. Dermatopathol Pract Concept. 2000;6:348–55. Zelger B, Soyer HP. Between Scylla and Charybdis; mythology in dermatopathology. Dermatopathol Pract Concept. 2000;6:348–55.
16.
Zurück zum Zitat Sakamoto A. Atypical fibroxanthoma. Clin Med Oncol. 2008;2:117–27.PubMed Sakamoto A. Atypical fibroxanthoma. Clin Med Oncol. 2008;2:117–27.PubMed
17.
Zurück zum Zitat Thum C, Hollowood K, Birch J, Goodlad JR, Brenn T. Aberrant Melan-A expression in atypical fibroxanthoma and undifferentiated pleomorphic sarcoma of the skin. J Cutan Pathol. 2011;38(12):954–60.PubMedCrossRef Thum C, Hollowood K, Birch J, Goodlad JR, Brenn T. Aberrant Melan-A expression in atypical fibroxanthoma and undifferentiated pleomorphic sarcoma of the skin. J Cutan Pathol. 2011;38(12):954–60.PubMedCrossRef
18.
Zurück zum Zitat Aung PP, Sarlomo-Rikala M, Lasota J, et al. KBA62 and PNL2: two new melanoma markers—immunohistochemical analysis of 1563 tumors including metastatic, desmoplastic, and mucosal melanomas and their mimics. Am J Surg Pathol. 2012;36:265–72.PubMedCrossRef Aung PP, Sarlomo-Rikala M, Lasota J, et al. KBA62 and PNL2: two new melanoma markers—immunohistochemical analysis of 1563 tumors including metastatic, desmoplastic, and mucosal melanomas and their mimics. Am J Surg Pathol. 2012;36:265–72.PubMedCrossRef
19.
Zurück zum Zitat Ramos-Herberth FI, Karamchandani J, Kim J, Dadras SS. SOX10 immunostaining distinguishes desmoplastic melanoma from excision scar. J Cutan Pathol. 2010;37:944–52.PubMedCrossRef Ramos-Herberth FI, Karamchandani J, Kim J, Dadras SS. SOX10 immunostaining distinguishes desmoplastic melanoma from excision scar. J Cutan Pathol. 2010;37:944–52.PubMedCrossRef
20.
Zurück zum Zitat Kanik AB, Yaar M, Bhawan J. p75 nerve growth factor receptor staining helps identify desmoplastic and neurotropic melanoma. J Cutan Pathol. 1996;23:205–10.PubMedCrossRef Kanik AB, Yaar M, Bhawan J. p75 nerve growth factor receptor staining helps identify desmoplastic and neurotropic melanoma. J Cutan Pathol. 1996;23:205–10.PubMedCrossRef
21.
Zurück zum Zitat Karamchandani JR, Nielsen TO, van de Rijn M, West RB. Sox10 and S100 in the diagnosis of soft-tissue neoplasms. Appl Immunohistochem Mol Morphol. 2012;20(5):445–50.PubMedCrossRef Karamchandani JR, Nielsen TO, van de Rijn M, West RB. Sox10 and S100 in the diagnosis of soft-tissue neoplasms. Appl Immunohistochem Mol Morphol. 2012;20(5):445–50.PubMedCrossRef
22.
Zurück zum Zitat González-Vela MC, Salcedo W, Neira C, González-López MA, Ayala H, Val-Bernal JF. Atypical fibroxanthoma developing on a pacemaker pocket mimicking a pyogenic granuloma. Cardiovasc Pathol. 2013;22(1):102–4. 2012 Apr 11 (Epub ahead of print).PubMedCrossRef González-Vela MC, Salcedo W, Neira C, González-López MA, Ayala H, Val-Bernal JF. Atypical fibroxanthoma developing on a pacemaker pocket mimicking a pyogenic granuloma. Cardiovasc Pathol. 2013;22(1):102–4. 2012 Apr 11 (Epub ahead of print).PubMedCrossRef
Metadaten
Titel
Atypical fibroxanthoma—a diagnosis of exclusion!
verfasst von
Assoc. Prof. Georgi Tchernev
Prof. Michael Tronnier, MD
Julian Ananiev, MD, PhD
Teodora Taneva
Prof. James W. Patterson, MD
Assoc. Prof. Maya Gulubova, MD, PhD
John P. Trafeli
Assoc. Prof. Antonina Gegova
Mason Harrell, MD
Claudio Guarneri, MD
Prof. Uwe Wollina, MD
José Carlos Cardoso, MD
Nobuo Kanazawa, MD, PhD
Assoc. Prof. Liliya Zisova, MD, PhD
Assist. Prof. Ana-Maria Forsea, MD, PhD
Prof. Christos C. Zouboulis
Publikationsdatum
01.08.2013
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 15-16/2013
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-012-0173-1

Weitere Artikel der Ausgabe 15-16/2013

Wiener Medizinische Wochenschrift 15-16/2013 Zur Ausgabe